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Controlled drug release plays an important role in medicine because it can be a factor 
in human health care. It is defined as the ability to release a drug inside the body at a specific 
time. Radiation-sensitive functionalized materials can be controlled by outside triggers such 
as radiation and have great potential for application in controlled and targeted drug delivery. 
Radiation-sensitive functional groups are known and studied, however, there are very few 
examples. Previous studies have revealed that 2-oxoalkyl group can successfully undergo 
radiolytic cleavage, but under relatively high doses of radiation. It is desirable that the 
radiolysis efficiency of 2-oxoalkyl group be improved in order to gain applications in clinical 
medicine. Thus, one objective of this thesis was to study the effect of a few substituents on the 
radiolysis efficiency of substituted 2-oxoalkyl groups. Therefore, a few molecular probes that 
contain an aryl 2-oxoalkyl group with substituted acetophenone of monoesters of adipic acid, 
and coumarin scaffold of monoesters of adipic acid have been successfully synthesized. 
These compounds were studied under X-ray radiation at various doses to assess the potential 
of selective cleavage of the aryl oxo-methyl ester linkage. The radiolysis studies showed that 
less than 10% of the ester linkages in these compounds were degraded under a dose of up to 
20 Gy of radiation. Compounds were also studied for their hydrolytic rate for the aryl oxo-
methyl ester linkage using TLC method. Hydrolysis at around neutral pH happened at a slower 







Poly-L-glutamic acid (PGA) is a natural polypeptide that is biodegradable and 
biocompatible. Therefore, it has been exploited as drug carrier system. In this thesis, PGA has 
been modified with a phenacyl group. The lipophilic phenacyl group is assumed to assist the 
formation of nanoparticles for the modified PGA. Radiolysis studies of such modified PGA 
showed that the grafted phenacyl group can be selectively cleaved upon radiation with a 
clinically relevant dose.  
Lawsone is a commercially available natural product. It has been used as starting 
material for the synthesis of different biologically active compounds. Lawsone also has various 
biological effects including anticancer activity. One anticancer mechanism of lawsone is 
associated with its ability to undergo one-electron reduction. Thus, another aspect of this 
thesis was to synthesize lawsone derivatives as potential anticancer agents. The preparation 
of glycosylated lawsone derivatives was of particularly interest. Direct glycosylation of lawsone 
using a number of methods was unsuccessful in providing fully deprotected lawsone 
glycosides. Then the Mannich reaction was employed to produce a group of lawsone 
derivatives including one compound bearing a glucose residue. The synthesized lawsone 
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1.   Introduction  
 
1.1. Cancer  
 
		
	 The American Cancer Society reports that more than 1,500 people die each day due to 
cancer. Currently, radiotherapy, chemotherapy and surgery are the possible treatment options 
for cancer. Chemotherapy treatment involves drugs to treat cancer or relieve cancer 
symptoms. Often the combination of chemotherapy, radiotherapy and surgery is necessary 
and useful to overcome cancer. Radiotherapy and surgery are the localized therapies that 
work only when malignant cells are confined to the treated area. Thus, chemotherapy is 
crucial for the systemic treatment of metastases relating to the local and regional growth of 
tumors.1   	
The anticancer drugs used in chemotherapy are systemic anti-proliferative agents that 
prefer to kill the dividing cells. However, the prolonged use of chemotherapy results in lethal 
damage to proliferating normal cells along with the tumor cells.2 Therefore, most 
chemotherapeutic agents suffer from low selectivity towards tumor cells, and low therapeutic 
index. The side effects diminish the extent of the dose that can be administered to treat 
tumors. 3	 
1.2. Anti-cancer drug delivery  
 
Novel drug delivery systems aim at increasing the benefit of drugs and decreasing side 
effects, 4 with a goal of increasing their pharmacokinetics and their biodistribution.5 Anticancer 
drugs in conventional chemotherapy are not specific or targeted to the cancer cells; therefore, 
13	
	
targeted delivery of anticancer drugs to cancer tissues is being developed to meet the 
challenge.6 
Drug delivery systems can increase the bioavailability of drugs by entrapment of the 
drugs within a suitable carrier such as liposomes and micro/nanoparticles of natural or synthetic 
polymers.7 Therefore, the objective of all drug delivery system is to distribute medications to 
specific body parts through an agent that can control drug bioavailability by a physiological or 
chemical trigger.8 To achieve this goal polymeric microspheres, polymer micelles and hydrogel-
type materials have been demonstrated to improve drug targeting specificity, decreasing the 
drug toxicity, decreasing dosing frequency, and offering protection against biochemical 
degradation, which results in increasing treatment success rates.7  
1.3. Prodrug approach    
To improve the therapeutic activity and reduce the side effects of current anticancer 
drugs, anticancer prodrugs have to be developed. Prodrugs are advantageous in affecting 
tumor cells and safe to normal cells.3 The design of a prodrug aims to make the active drug 
work on the specific spot, to offer the necessary pharmacological impact, and to limit side 
effects.9 
Consequently, the goal of prodrug design is to temporarily change the physicochemical 
properties of drugs in order to modify drug pharmacokinetics, prolong action, decrease 
toxicities and side effects, enhance selectivity, and solve challenges related to formulation. 10 
This can be achieved by a variety of mechanisms that include hypoxic reduction in solid 
tumors, activation by enzymes overexpressed in tumor tissues, and targeting of antigens or 
receptors specifically expressed on tumor cell surface.3 Therefore, using targeted anticancer 
14	
	
prodrugs for tumor spot selective activation is an effective approach for improving 
chemotherapy.11 
 
1.4. Stimuli-responsive polymers in drug delivery  
 
New polymers are now being developed that are able to act in response to their 
environment by changing their physical and chemical properties.12 These polymers have been 
designed to respond to various types of stimuli, such as pH, temperature, mechanical force, 
various small molecules and biomolecules that are present, as well as electric/magnetic fields. 
As a result, the polymers are called “stimuli-responsive polymers” or “smart/ intelligent 
polymers”. 12 For example, pH-responsive polymers can be reversibly manipulated by changes 
in external pH. This approach can be used for anticancer drug delivery since for most tumors’ 
the extracellular pH is more acidic (5.8-7.2). Thus, the release of a drug can be initiated via 
manipulating the pH.13	Another example of stimuli-responsive systems is a photo-responsive 
system that uses light. This can be utilized in polymer chemistry as an energy source for 
polymer synthesis, as well as an information source or a trigger, controlling reversibly the 
physical and chemical properties of polymers.14  
1.5. Radiation-sensitive functional groups 
  
Very few radiation-sensitive functional groups are known and have been studied. 
Consequently, a radiation-responsive drug delivery system is rarely studied. One functional group 
that has been reported to undergo radiolytic cleavage is the 2-oxoalkyl group. Some studies revealed 
that the carbonyl group positively affected the release of the leaving group X (Scheme 1) through 
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one-electron reductive pathway.15 Antitumor drugs such as, fluorodeoxyuridine (5-FdUrd) that are 
toxic to normal cells as well as to tumor cells have been connected to 2-oxoalkyl groups to make 
prodrugs that can be activated through radiation.16 Exposure to radiation can be controlled and so, 
much like a prodrug, the radiolytic drugs can become active in a specific area, during a particular 
time, and with a specific dosage.15  
An activation mechanism (Scheme 1) has been proposed, in which one-electron is absorbed, 
and can enter to the π* of the double bond (b). Moreover, by thermal activation the electron in 
the π* can enter into the σ* (c) that leads to a weakened σ bond that can cleave readily (d). 
Without the 2-oxoalkyl groups, the reaction does not continue. Furthermore, under aerobic 
conditions, this reaction does not happen17 because the oxygen can prevent radiolytic 
reduction and make a superoxide anion radical.  
 
Scheme 1: Proposed mechanism for one-electron reduction. 
Another molecule, indolequinone was studied for its radiolytic cleavage as well as bio-
reductive cleavage.  Activation of the indolequinone (e) under reductive conditions results in 
the formation of hydroquinone (f) or the semiquinone radical (g). This reaction may occur 
under hypoxic condition resulting in the reduction by one-electron or by two-electron reducing 
enzymes, and these reactions, along with the effect of oxygen on leaving group to produce h 




Scheme 2. Pathway of indolequinone reduction18  
 
There are several other functional groups in which the reductive cleavage of a leaving 
group has been observed/assumed to occur in biological systems through enzymatic 
processes. The functional groups studied include nitrobenzyl (j), nitroimidazolyl (k) and 
benzoquinone (l) as shown in Figure 1. The nitrobenzyl can cleave upon one-electron 
reduction in under hypoxic conditions. This reactivity has been reported in biological systems 
17	
	
and enzyme-catalyzed processes. Nitroimidazolyl showed that it can increase its cytotoxicity 
and hypoxia selectivity in radiotherapeutic outcome in vivo. In addition, benzoquinone 




Figure 1. Structures of nitrobenzyl group (j), nitroimidazolyl group (k), and benzoquinone  
                     group (l)	
  
1.6. Poly-L-glutamic acid (PGA)  
 
 
In recent years biocompatible polymers gained much attention in the research 
community. These macromolecules have specific pharmacokinetic characteristics, such as 
prolong blood circulate, strengthening retention of tissues; along with creating advantageous 
accumulation in lesions that have leaky vasculature.19 Consequently, polymers have become 
useful drug delivery tools. Moreover, the fusion of small molecular weight anticancer agents to 
biocompatible polymers can enhance drug deposition at the tumor site and decrease 
dangerous outcomes of the drug on normal tissues.   
For instance, poly-L-glutamic acid is a useful carrier of cancer therapeutics and imaging 
agents.20 Poly-L- glutamic acid polymers can be conjugated to anti-oxidative agents without 
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impacting the pharmacological properties of the drugs. Due to such characteristics, these 
polymers have potential as renal targeting drug carriers.21 
Poly-L-glutamic acid is a polypeptide made up of L-glutamic acid. It has two forms, poly-α-L-
glutamic acid and poly-γ-L-glutamic acid according to whether the α or γ carboxy group is 
involved in the formation of the peptide bond. Their structures are shown in Figure 2. 22 
Poly-!-L-glutamic acid is a naturally-occurring polymer which can be isolated from bacteria, 
especially those of Bacillus species, or from a traditional food in Japan called Natto.23 The 
application of poly-!-L-glutamic acid has been increasing rapidly due to its ability of being 
biodegradable, edible and non-immunogenic.22 
 
 Poly-α-L-glutamic acid, which will be referred to in this thesis later on as poly-L-
glutamic acid (PGA), is made up of naturally occurring L-glutamic acid monomers bonded to 
each other with amide bonds.  In this polymer, L-glutamic acid monomers are connected 
between the "	–carboxyl and the " -amino groups of adjacent monomers. 24 The pendant free 
! carboxyl group in each repeating unit of L-glutamic acid carries a negative charge at a 
neutral pH. As a result, the polymer becomes slightly water-soluble. The carboxyl groups 
facilitate chemical modification of the polymer or drug attachment.20 PGA is also 






Poly-α-L-glutamic acid                         Poly-!-L-glutamic acid 
            Figure 2.  Structures of poly-α-L-glutamic acid and poly-!-L-glutamic acid 
These characteristics make PGA the right factor for polymer–drug conjugates that can be 
used for selective delivery of chemotherapeutic agents.  A number of antitumor agents including 
doxorubicin, daunorubicin, 1-β-D-araninofuranosylcytosine (Ara-C), uracil and uradine, 
cyclophosphamide, L-phenylalanine mustard, as well as mitomycin C, have been conjugated to 
PGA .20 Virtually all of these PGA conjugates have led to better antitumor activity than the parent 
drug.20 We are interested in the modification of PGA with functional groups that could be cleaved 
by a dosage of radiation.      
1.7. Quinones  
 
Many drugs currently contain the quinone functional group.26 Quinones are very important 
in chemistry and biochemistry.27 
There are two major mechanisms that are behind the cytotoxic and anticancer characteristics 
of the natural quinone structure. Several enzymes can reduce quinone to hydroquinone, which 
results in the formation of a fully aromatic system.11 The first pathway, through the one-electron 
reduction, provides the semiquinone radicals via reductive enzymes such as cytochrome P450 
reductase and NADH dehydrogenase. The other pathway occurs through a two-electron 
20	
	
reduction pathway to produce hydroquinone via reductive enzymes such as DT-diaphorase 
(Scheme 3). 28 
 
                   Scheme 3: Pathway of quinone reduction 29  
One of the active compounds in biology is 1,4-naphthoquinone. Naphthoquinones are widely 
available in nature; they are often found in bacteria, fungi, and in several plants.29 1,4-
Naphthoquinone is often found in a genus of Diospyros L., which is the largest genus in the 
Ebenaceae family of plants that includes around 500 species. This genus appears in both tropical 
and temperate regions.28 
 
Figure 3. Naphthoquinone structure 
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The efficacies of these compounds against tumor cells have been shown by various 
studies that have demonstrated various modes of action. For example, a study indicated that a 
natural benzoquinone derivative had enhanced anti-proliferative and apoptotic activities against 
human hormone-refractory prostate cancer cells (PC-3 and DU-145). 24 These compounds need 
reductive activation in order to form electrophilic species that are toxic to cells. Furthermore, the 
drugs act as substrates for the reductases found in most of the cells. These drugs can address 
solid tumors with defined hypoxic fractions and tumor tissues with the activating enzymes.18 
 
The bioreduction of naphthoquinones is affected by their redox properties; the ability of 
these compounds to accept electrons can be changed by adding substituents. Thus, the 
substituents become electron acceptors or donors to the naphthoquinone rings.30 
 
1.7.1   2-Hydroxy-1,4-naphthoquinone (lawsone) 
 
One of the naturally occurring naphthoquinones is lawsone, also called 2-hydroxy-1,4-
naphthoquinone (Figure 4). Lawsone is responsible for the red dye of henna. In some 
countries, henna is used for coloring hair, as well as dying nails and skin. In addition, it has 
some medicinal benefits. For example, it can be used to treat burns.31 Henna also have a 
positive effects on treating microorganisms, headaches, lumbago, bronchitis, ophthalmic, 
syphilitic sores and amenorrhoea.32 They also have antibacterial properties. The most 
important benefit of lawsone is its anticancer property. Lawsone prevents the development of 
cancer and inhibits cancer cell growth. Thus, this compound can be helpful in developing 





Figure 4. Lawsone structure 
 
The majority of lawsone’s biological activity arises from and can be explained by the redox 
cycling and alkylating properties lawsone possesses.33 Through oxidation or alkylation of 
cellular structures, lawsone targets and damages the cells, potentially causing their death. This 
element is exploited during the use of lawsone in cancer therapy. In this case, cancer cells are 
more susceptible to oxidative damage as compared to their non-cancerous counterparts.  
Thus, lawsone can be used to kill the cancerous cells while sparing the non-cancerous ones.33 
 
 1.7.2 Redox properties of lawsone 
 
 
In the treatment of cancer, the redox cycling is important to the metabolism of lawsone.34	
The quinone function of lawsone can be reduced to the semiquinone and thus to the 
hydroquinone through a chain of two one-electron reductions (Scheme 4). These species are 
reoxidized by molecular oxygen (O2) and create reactive oxygen species (ROS), such as 
superoxide, hydroxyl radical and hydrogen peroxide.29 The superoxide radical is a very reactive 
species and it is unstable. This instability results in the formation of hydrogen peroxide, which is 
toxic to cells because it can permeate membranes. ROS are dynamic-oxidizing agents and they 
23	
	
can most likely damage macromolecules such as DNA, proteins and lipids. Thus, ROS can lead 




Scheme 4: Redox properties of lawsone 29 	 
 
1.7.3 Preparation methods for lawsone 
The synthesis 2-hydroxy-1,4-naphthoquinone has been derived through two main 
methods: 1) by ring construction or 2) by the use of naphthalene derivatives as starting 
materials.32 
The first method involved the compound 3-methyl-1H-indane, which was oxidized by sodium 
dichromate, - converted to phenylacetic acid and cyclized to produce lawsone as shown in 
Scheme 5. 35 
 
  
Scheme 5.  Preparation of lawsone 33 
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The other method was achieved by using the economical naphthalene.  Some 
examples of the most useful starting materials for making lawsone (Scheme 6) are examined 
below. 1-Amino-2-naphthol which is one of the starting materials, has been used with sodium 
bisulfite in aqueous 6N sodium hydroxide to produces 1-amino-2-napththol-4-sulfonic acid, 
which upon hydrolysis with concentrated sulfuric acid in methanol, leads to 2-
methoxylawsones.32 $-naphthol is another example of the starting material that is converted 
into $-naphthoquinone which reacts with acetic anhydride-sulfuric acid to produce 1,2,4-




Scheme 6.  Other methods used to prepare lawsone 32  
 





The anticancer agents conjugating with sugar residues have received a lot of attention 
in recent years. Unlike normal cells, cancer cells have the ability to accept larger amount of 
glucose as explained by the Warburg effect.37 Glycoconjugation means linking a drug to 
glucose or other sugar in order to improve cancer targeting and selectivity.38 
Some anticancer drugs contain glycosylated natural products. For example, Digoxin is 
a well-known glycoside drug that has anticancer activity.39 The most important features of the 
sugar moieties present are increased water solubility, and thus the enhanced bioavailability of 
such compounds.   
 
Figure 5. Digoxin structure 39 
Over-expression of glycolytic enzymes and insulin-independent glucose transporter 
GLUT-1 mediates the effect, which has been recognized as a hallmark of cancer 
development. 37 The idea of using glucose as cancer targeting molecular tool has been 
exploited. Several studies have shown that antitumor drugs bearing glucose residues display 







1.9. Objectives  
 
 
Currently, the aim of cancer research is to design a drug that is made up of cytotoxic 
compounds that selectively interact with molecules and target tumor cells with minimal toxicity 
to normal cells.  
 In this thesis we are going to study two separate yet related research topics: one is the 
radiolytic cleavage of aryl-substituted 2-oxoalkyl groups through one-electron reduction 
process induced by radiation; and the other is the synthesis of naphthoquinone derivatives 
that are potential anticancer agents after activation through one electron biochemical 
reduction. Thus, the following specific objectives of the thesis are identified. First, a group of 
molecular probes containing an aryl-substituted 2-oxo group will be synthesized for radiolytic 
studies aiming to improve radiolytic efficiency. Second, the biocompatible poly-L-glutamic acid 
(PGA) will be modified with a radiation-labile functional group to produce radiation-sensitive 











2. Results and discussion 
2.1. Radiation-sensitive molecular probes  
2.1.1. Synthesis of molecular probes for radiolysis study 
  
Radiation–sensitive functional groups can respond to X-ray or gamma ray radiation and 
undergo selective cleavage of certain bond.  The 2-oxoalkyl group has been reported to 
undergo radiolytic cleavage.  In addition, this group is removed by X-ray radiation under 
hypoxic conditions in an aqueous solution. 40 Under hypoxic conditions, X-ray radiation 
produces hydrated electrons, as well as hydrogen radicals and hydroxyl radicals in an 
aqueous medium. 40 
 
One problem associated with the radiolytic cleavage of 2-oxo-alkyl group is that it needs a 
relatively large dose of radiation; however, we are hoping to achieve te cleavage of such a 
group under clinically relevant radiation doses (< 30 Gy).   
 According to the proposed radiolysis mechanism of 2-oxo-alkyl group (Scheme 7), this 
radiolysis rate may be affected by the following factors:  
a) The ease of the compound in absorbing electron(s) 
b) The leaving ability of the leaving group  






Scheme 7.  The mechanism for one-electron reduction. 
 
Previous studies have shown that an aromatic functionality in the neighboring environment 
of the 2-oxo-alkyl group can accelerate its radiolytic cleavage.16 Here we anticipate that an 
aromatic ring directly linked to the 2-oxo-alkyl group may be able to enhance its radiolytic rate. 
In order to improve the radiolytic efficiency of 2-oxo-alkyl group, we plan to attach an aromatic 
ring to the 2-oxo-alkyl group. According to the proposed activation mechanism (Scheme 7), 
structure m can absorb one electron which can enter into the π* of the C=O double bond. By 
thermal activation the electron in π* can enter into the σ*, which leads to a weakened %	bond 
that can cleave readily. The aryl functionality in the aryl 2-oxo-alkyl group is assumed to 
facilitate the fast capture of electron(s) and the stabilization of free radical species (n - p). 
These features are expected to result in a faster radiolytic cleavage of the aryl 2-oxo-alkyl 
group than the simple 2-oxo-alkyl group. The relative stability of the initial free radical (p) 
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generated from the radiolytic cleavage probably plays an important role in the final step of the 
cleavage. Since free radicals display the following trend of stability: 3o > 2o > 1o, alkyl 
substitutes at the carbon atom next to the oxo-group will stabilize the free radical and 
consequently accelerate the cleavage of the C-X bond in structure (p).  
A group of molecular probes (1 - 6, Figure 6) have been designed to study the effect of 
these structure features on the radiolysis rate of aryl 2-oxo-alkyl group. Structures 1 - 5 are 
derivatives of simple acetophenone or substituted acetophenone and structure 6 contains a 
coumarin scaffold. All these molecules are monoesters of adipic acid. We are going to study 
poly-L-glutamic acid (PGA) modification, which has multiple carboxylic acid groups. Therefore, 
we have designed those molecular probes having one carboxylic acid functional group to 
resemble L-glutamic acid residues of the polymer. The carboxylic acid group in these probes 
will also make these molecules more hydrophilic and increase their water solubility.  
  
 




For the preparation of probes 1 – 4, adipic acid was reacted with one equivalent of a 
bromoacetophenone derivative (7a, 7b, 8a, and 8b) in triethylamine (Et3N) and EtOAc at room 
temperature to provide monoester (1 - 4) in 20% to 60% yield (Scheme 8). The corresponding 
diesters (9 – 12) were also obtained as the minor product for each of these reactions. The 




Scheme 8. Synthesis of designed compounds (1 - 4) 
 
For the preparation of probe 5, we did not use the reagent 2-bromo-2 
methylpropiophenone to react with adipic acid. It is likely that the bromide would react with the 
acid via an SN2 mechanism, which is anticipated to be very slow for this 3o bromide. Therefore, 
we tried to form this ester through an acid and alcohol as shown in Scheme 9. This reaction 
happens through a mechanism of Steglich esterification reaction.  The synthesis of 5 and 14 
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was started with 2-hydroxy-2-methylpropiophenone that was combined with adipic acid, 4-N, 
N-dimethylaminopyrdine (DMAP) and N, N–diisopropylcarbodiimide. The reaction was first 
tried in dimethylformamide (DMF) as solvent at either room temperature or 50℃, but it gave 
mixed products that was difficult to purify. Changing the solvent to dichloromethane (DCM) at 
room temperature provides the desired product (5) in 19% yield and the corresponding diester 





Scheme 9. Synthesis of probe 5 
 
Probe 6 contains a coumarin scaffold which can be viewed as an extended aryl system 
with fluorescent property. For the preparation of 6, adipic acid was reacted with 3-
(bromoacetyl)-coumarin in the presence of triethylamine as the base at room temperature. 
However, the reaction was not efficient and the product was an inseparable mixture as TLC 
showed. Changing the base to sodium bicarbonate was attempted; TLC investigations 
revealed that the reaction did not occur either at room temperature or under reflux. However, 
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using N,N,diisopropylethylamine (DIPEA) in EtOAc as the solvent under reflux temperature 
gave successfully the desired product 6 in 17% yield. The diester (16) was also formed in 
small quantity (2% yield) in this reaction. The structures of these compounds were confirmed 
by1H NMR, and 13C NMR. 
 
 
Scheme 10. Synthesis of molecular probe 6 
 
2.1.2. Synthesis of tyrosine derivatives  
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The 2-oxoalkyl group has been reported in the literature to undergo radiolytic cleavage 
when it is linked to a leaving group. One particular example is a tyrosine derivative in which 
the 2-oxoalkyl group is connected to the phenolic hydroxyl group (19, Scheme 11). 16  Under 
hypoxic conditions, the 2-oxopropyl group in 19 can be released by radiolytic one-electron 
reduction.16 Here we repeated the synthesis of 19 according to the published procedure.16 
Compound 19 is to be used as a positive control for the radiolytic studies of the synthesized 






Scheme 11. Synthesis of tyrosine derivatives 
 
 
2.1.3. Synthesis of cholesterol derivatives 
 
 
  A cholesterol fragment is a large hydrophobic group, and not toxic.  It has been widely 
used as a lipophilic tag to modify biologically interesting molecules.41 When cholesterol is 
incorporated with radiation sensitive groups, large structural changes due to large increase in 
lipophilicity can be expected for the molecule being modified.  
Here we prepared cholesterol derivative 21 with an acid functionality (Scheme 12). The 
34	
	
synthesis of 20 was started with solution of sodium hydride in tetrahydrofuran stirred at room 
temperature then followed by adding cholesterol and tert-butyl bromoacetate. The mixture was 
stirred at 80℃ to provide 20 in 67% yield. Then, 20 was dissolved in DCM and treated with 
trifluoroacetic acid-water (95:5) at 0℃ to provide 21.  
Compound 21 can, in theory, be linked to a radiation sensitive group, such as the group 
containing an aryl 2-oxo-alkyl moiety. However, since the synthesized probes (1 - 6) did not 
show favorable radiolytic properties (see section 2.1.5), the idea of incorporating the 





Scheme 12.  The synthesis of cholesterol derivative 
 
2.1.4. Synthesis of modified poly-L-glutamic acid (PGA) 
 
Poly-L-glutamic acid (PGA) is a biocompatible polymer that shows great potential as 
drug carrier. Each side chain of the amino acid residues in PGA has one free carboxylic acid 
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group which is the basis for chemical modification. Modification of PGA with a lipophilic group 
can produce modified PGA (m-PGA), which may facilitate the formation of nanoparticles 
suitable for drug delivery. In addition, when the lipophilic group contains radiolytically labile 
chemical linkage(s), such m-PGA will be responsive to radiation. Drug carriers comprising of 
such radiation-sensitive material can achieve controlled drug releases upon activation by 
radiation. Towards this end, we have prepared a couple of m-PGA products modified with 
phenacyl group. 
 The commercially available PGA sodium salt was treated with HCl (pH = 1) to give the 
acid form of PGA (Scheme 13). PGA was then treated with phenacyl bromide and 
triethylamine (Et3N) in dry DMF at 40oC to provide modified PGA. By using different amounts 
of reagents, one could achieve different degrees of modification. Table 1 summarizes two 
reaction conditions and the corresponding product details.  Upon the completion of the 
reaction, the product was precipitated out by adding hexane-ethyl acetate (1:1, v/v), washed, 
and collected after centrifuge. The recovered yield of the material is typically over 80% 
according to this procedure (entry 1 in Table 1). However, 1H NMR spectral data of the product 
m-PGA-Ph-24 indicates the presence of triethylamine, presumably in the form of HBr salt 
and/or carboxylic acid salt of the glutamic acid residues. In order to remove triethylammonium 
salt, the work-up procedure of product m-PGA-Ph-32 (entry 2, Table 1) was modified. The 
initial product obtained from the procedure described earlier was re-dissolved in DMF and then 
re-precipitated out from water. 1H NMR spectral data of m-PGA-Ph-32 indicates that the 
triethylammonium salt is no longer present.   
 The structures of m-PGA were all confirmed by 1H NMR spectral data. Typically, a 
proton signal at around d 5.5 ppm corresponds to the CH2 residue of the phenacyl group and 
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the signal at around d 4.8 ppm resulted from the proton at the a-carbon of the glutamic acid 
residue. The integration ratio of these two signals can be used to calculate the % of side chain 




Scheme 13.  Preparation of modified poly-L-glutamic acid (m-PGA).  
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2.1.5. Radiolytic studies of synthesized probes 
 
 
 The radiolysis data for sections 2.1.5 and 2.1.6 were provided by our collaborator Dr. Wilson 
Roa at Cross Cancer Institute & the University of Alberta, Edmonton, Alberta, Canada.  
The synthesized probes (1, 2, 4 and, 5) were subjected to X-ray radiation at different 






























while compounds 3 and 6 were not determined because these two compounds were prepared 
after the evaluation of other compounds had been completed. After irradiation, the 
concentration of the original compound in each sample was measured by HPLC after 24 h and 
the results are summarized in Table 2. The data indicates that less than 10% of the sample 
was degraded when each of the probes was treated with X-ray radiation at a dose up to 20 
Gy. The value in parenthesis indicates the % of decrease (–) or increase (+) of the 
concentration after irradiation relative to the control. Although compound 1 (having 8.5% 
degradation at 5 Gy) appears to have a higher degree of degradation than other compounds, 
the relatively low % of cleavage does not make such comparison meaningful. Thus, the 
structural influence on the radiolysis rate cannot be concluded based on these preliminary 
data.  
 
Table 2. Change of sample concentration of probes (1, 2, 4, and 5) after X-ray irradiation 
 
Compound 
Concentration (mg/mL) (±%) 
Dose 0 Gy Dose 5 Gy  Dose 10 Gy Dose 20 Gy  
        1 
0.684 0.626 (– 8.5)  0.649 (– 5.1) 0.648 (– 5.3) 
2 
0.621 0.584  (– 6.0) 0.607 (– 2.3) 0.605 (– 2.6) 
3 
Nd nd nd Nd 
4 
0.657 0.606  (– 7.8) 0.631 (– 4.0) 0.628 (– 4.4) 
5 0.530 0.534 (+ 0.01) 0.556 (+ 4.9) 0.557 (+ 5.1) 
6 Nd nd nd Nd 




Compound 1 was also subjected to radiation under a much higher dose. Table 3 shows 
the sample concentration changes as a result of X-ray radiation under different doses. Again, 
the value in parenthesis indicates the % of decrease (–) or increase (+) of the concentration 
after the irradiation relative to the control. Radiation at a dose up to 200 Gy led to only about 
6% of the sample being degraded. The data indicates that radiolytic cleavage is not significant 
even at a radiation dose that is much higher than the clinically relevant dose. For comparison 
purpose, compound 19 (Scheme 11) was also subjected to radiolysis study along with 
compound 1. The results indicated that only a small percentage (< 10%) of compound 19 
underwent radiolytic cleavage under the radiation dose of up to 200 Gy (data not shown). This 
is in contrast to the report earlier that the same compound 19 underwent about 30% selective 
radiolytic cleavage at an radiation dose of 150 Gy.16 It is speculated that the experimental 
condition for radiolysis studies in our collaborator’s lab has not been optimized. Radiolysis 




Table 3. Concentration change of compound 1 after X-ray radiation at different doses  
X-ray dose (Gy) C1 (µg/mL) C2 (µg/mL) C (average, µg/mL) (±%) 
0 10.33 10.18 10.26 
20  10.52  10.40 10.46 (+ 1.9) 
100 9.87 9.69 9.78 (– 4.7) 




 At this point the radiolysis data for these synthetic probes are still preliminary results. It 
is still under investigation to determine the optimal experimental conditions for radiolysis 
studies. More experiments are needed in order to optimize the experimental conditions and 
fully characterize the degradation products.  
 
2.1.6. Radiolytic studies of modified PGA 
 
 The m-PGA samples were subjected to X-ray radiation to study their radiolytic 
properties. Typically, an m-PGA sample was first dissolved in dimethylsulfoxide (DMSO) and 
then dd-H2O was added. The resulting suspension was centrifuged, washed with dd-H2O and 
then re-suspended in dd-H2O for radiolysis study15. The sample was radiated with X-ray 
radiation (200 kV, 15 mA) at a dose up to 30 Gy. The phenacyl group cleaved from m-PGA 
resulted in some aromatic compounds that were extracted with EtOAc and analyzed with UV 
spectroscopy. The UV absorbance was used to show the radiolysis effect. Figure 6 shows the 
radiolysis effect of one specific m-PGA under the dose of 5 Gy, 10 Gy or 30 Gy. The data 
shows that X-ray radiation significantly increases the cleavage of the phenacyl group in m-
PGA. The fact that the control sample without radiation (0 Gy) also produces UV-absorbance 
suggests that auto-hydrolysis of the phenacyl ester group might have occurred to some extent, 









Figure 7. X-ray radiolysis result of m-PGA 
 
 
2.1.7. Hydrolysis studies of synthesized probes 
 
 
Radiolysis studies with m-PGA samples suggest that the phenacyl ester bond might 
undergo auto-hydrolysis. The substitution at the "-position of the carbonyl group (R1 and R2) 
may increase the rate of radiolytic process but slow down the auto-hydrolysis rate of the ester 
linkage under physiological condition. In order to understand the effect of different substituents 
on the relative stability of phenacyl esters, we have qualitatively investigated the hydrolysis 
rate of molecular probes (1, 2, 4 and 5, Figure 8). 
 



























Figure 8. Structures of probes for hydrolytic studies  
 
 The hydrolysis rate of molecular probes (1, 2, 4 and, 5) has been studied under 0.5 M 
NaH2PO4/Na2HPO4 buffer solution (pH 7.0) at room temperature (22oC) using qualitative TLC 
(thin layer chromatography) analysis. The chemical reaction is shown in Scheme 14 and TLC 
was used to monitor the progress of the reaction.  Results are presented in Figure 9.  The 
hydrolysis of 1, 2, 4 and 5 yields the corresponding aromatic alcohol 1a, 2a, 4a and 5a as the 
hydrolyzed product (Scheme 14), which can be readily detected by UV absorbance or 
staining. The relative intensity of the product spot to the starting material spot indicates the 
degree of hydrolysis in each case. The TLC data indicate that compounds 1 and 2 are 
accompanied with significant hydrolysis after four to five days under the above conditions. On 
the other hand, hydrolysis is not significant for compounds 4 and 5 after stirring for two weeks 
under these conditions. The results indicate that steric hindrance at "-position of the carbonyl 















                      
 
Figure 9. TLC results of the hydrolysis reaction of molecular probes 1, 2, 4 and 5 under 
pH 7 at 22oC with (hexane / ethyl acetate/ methanol = 1:1:0.2). SM: starting material; P: 
hydrolysis product (1a, 2a, 4a and 5a); Salt of SM: the sodium salt form of the starting 
material; on each TLC plate, the first column represents the pure starting material 
dissolved in ethyl acetate. The second column represents the mixture of the starting 








2.2. Synthesis of lawsone derivatives  
 
Lawsone (2-hydroxy-1,4-naphthoquinone) has the orange-red colour 
artefact that makes through the extraction or preparation of the dye from henna 
leaves.42 
Lawsone is structurally related to naphthalene and characterized by its two 
carbonyl groups at the 1,4-position, and as such, are named 1,4-
naphthoquinone. Carbonyl groups may also be present at the 1,2-position, with 
minor incidence. 29  
 
 
 Lawsone has various biological activities such as, antioxidant, anti-
inflammatory, antibacterial and anticancer activities.43 This is the reason why this 
type of natural organic compounds is attractive in different areas of research. 
Lawsone has been used as a starting material in the synthesis of many clinically 
useful anti-cancer compounds such as atovaquone, lapachol and dichloroallyl 
lawsone. 44  
We are interested in the preparation of glycosylated lawsone derivatives 




biological properties of lawsone. As discussed earlier in Section 1.8, cytotoxic 
drugs carrying a glucose residue may target cancer cells more selectively than 
normal cells. Therefore, glycosylated lawsone derivatives may be useful 
antitumor agents that have low toxicity to normal cells/tissue.37 
 
2.2.1. Attempts to synthesize glycosylated lawsone 
 
2.2.1.1. Synthesis of peracetylated glucosyl lawsone  
  
The synthesis began with the protection of all OH groups in glucose with 
acetic anhydride in the presence of pyridine at room temperature. This reaction 
resulted in product 22, which was found in one particular spot on the TLC. 
Furthermore, removal of the acetyl group in the anomeric position was done in 
one step. In this case, ammonium carbonate was utilized in anhydrous 
dimethylformamide (DMF) to provide 23; this compound needed to be purified by 
chromatographic separation. 23 was then treated by trichloroacetonitrile with 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) as catalytic base in anhydrous 
dichloromethane to give 24 in 90% yield.  This synthesis was carried out 
according to a reported procedure with some modification.45 Direct coupling of 
glycosyl imidate 24 with lawsone 25 was achieved in anhydrous tetrahydrofuran 
and dichloromethane with boron trifluoride diethyl etherate as the catalyst at 
room temperature, to provide 26 in 65% yield. In addition, 27 was yielded in 18%. 



















To deprotect acetyl groups on the glucose residue of 26, we used various 
basic conditions (Table 4), which led to an unexpected and undesired result of 
the cleavage of glycoside linkage (Scheme 16). First the removal of acetyl group 
in compound 26 by tetrahydrofuran (THF) and water in triethylamine (Et3N) was 
unsuccessful and TLC showed the formation of 25. A different base, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) was also tried. This was done with toluene 
solvent or methanol solvent, which showed a similar result.  Furthermore, 
guanidine-guanidinium nitrate (G/GHNO3) has been reported to be a very mild 
and efficient method to remove acetyl groups. 46 Therefore G/GHNO3 solution 
was prepared by using guanidinium nitrate in anhydrous MeOH/DCM and adding 
sodium methoxide (MeONa). Treatment of 26 with G/GHNO3 resulted in the 
formation of 2-methyl-1,4-naphthoquinone 29 which was confirmed by 1 HNMR 
data. 
 
 Table 4. Conditions used in deacetylation reaction 
 
      






   Reagent Temperature Solvent 
 I  Et3N rt. THF + H2O 
 ii  DBU rt. MeOH  
 iii  DBU 60 
o
C Toluene 
 iv Guanidinium + 
guanidinium nitrate 






Scheme 16. Deprotection of acetyl group 
 
This unexpected result can be explained by the possible mechanism 
shown in Scheme 17. Using the formation of 29 as an example, methanol 
functions as a nucleophile under weakly basic condition. First, a lone pair in 
methanol attacks through a simple nucleophilic addition to the α,β-unsaturated 
carbonyl system (a 1,4-addition reaction). The intermediate (r) then regenerates 
the carbonyl system with the OR group (sugar residue) functioning as a leaving 
group, leading to the formation of 29. The formation of lawsone 25 in these 
deacetylation reactions would follow a similar pathway wherein H2O is the initial 
nucleophile attacking the α,β-unsaturated carbonyl system followed by removal 









Scheme 17.  Proposed mechanism for the cleavage of glycosic bond  
 
 
2.2.1.3. TMS protection strategy  
 
 
Glycosylated lawsone with tetramethylsilyl (TMS) as the protecting group 
for the sugar OH groups was synthesized (Scheme 18). According to the known 





(Et3N) in dimethylformamide (DMF) to provide the desired product 30 with 88% 
yield. The protected compound 30 was treated by trimethylsilyl iodide in 
anhydrous DCM, which gave 31 in 74% yield.  Simultaneously, 1,4-hydroxy-
naphthoquinone 25 was reacted with sodium bis (trimethylsilyl) amide as base in 
THF at room temperature to provide a mixture of 32 and 33, which was further 
reacted with 31 in the presence of 15-crown-5. The reaction produced a mixture 
of products as indicated by multiple spots on TLC, presumably both 34 and 35, 
each of which as a β/α mixture. The mixture was not purified for structure 
characterization since TMS ethers are pretty unstable.  
Then, the product mixture (34/35) was subjected directly to deprotection in 
order to obtain lawsone glycosides with free sugar (36/37) under various conditions 
(Table 5). Unfortunately, all the trials were unsuccessful (Scheme 19). The first 
method involved methanol under reflux. This condition led to the decomposition of 
34/35 to form lawsone 25, which was noted by TLC. Moreover, amberlite IRC-50, a 
weakly acidic resin, in MeOH, was tried to achieve deprotection. This process gave 
a similar result as the one mentioned above. In addition, amberlite IRC-120 (H+ 
form) in MeOH provided 2-methoxy -1,4-naphthoquinone 29 which was confirmed 
by 1HNMR data. The formation of 25/29 under these conditions is probably via the 
same mechanism as described in Scheme 17.  TMS deprotection can generally be 






















i) Reflux MeOH 
ii) amberlite IRC- 
50 resin 
rt. MeOH 
iii) amberlite IRC- 
120 resin  














2.2.1.4. Attempted synthesis of C-glycosides of lawsone via 
aldol condensation reaction 
When a ketone enolate or enol reacts with an aldehyde, the reaction is 
called an aldol condensation and forms a new C-C bond. Lawsone is a typical 
enol (Scheme 20). In fact, lawsone has been used to couple with an aldehyde to 
form similar aldol condensation type of product.48 Through an aldol condensation 
lawsone can react with an aldehyde under mild conditions to give condensation 
product in very good yield.32  
 
Scheme 20. Lawsone as an enol 
 
 
A sugar (aldose) is an aldehyde in its open chain form. It can potentially 
react with lawsone to yield a C-glycoside of lawsone (Scheme 21). The reaction 
mechanism of this reaction is shown in Scheme 22. The reaction is expected to 
be catalyzed by a weak acid or base. Therefore, direct coupling of lawsone with 
glucose to give C-glycoside of lawsone has been tried under different conditions 
as shown in Table 6. Unfortunately, none of the conditions tried yields the 
desired product. Some reagents appeared to give new spots on TLC, but when 
purified only starting material lawsone was obtained. With beta-alanine 
























NaHCO3 / H2O 
 
rt.  / 60 
o
C / 100 
o
C  
NaOH / H2O rt.  / 60 
o
C  
H2SO4 / H2O rt.  / 60 
o
C / 100 
o
C  





C / 100 
o
C  
AcOH / H2O (1:1) 80 
o
C / 100 
o
C  
AcOH /Beta-alanine/ H2O (3:1) 50 
o
C / 80 
o
C  
AcOH + Beta-alanine 50 oC 
Et3N / THF rt.  / 69 
o
C 




imidazole / ethanol (1:1) 
 
rt. / 50 
o
C 
EtOH / H2O (1:1) rt. / 50 
o





AcOH / DMF 100 
o
C  
N, N-diisopropyl -ethylamine 
/DMF  
rt. / 50 
o









2.2.2. Synthesis of lawsone derivatives via Mannich reaction  
 The Mannich reaction is one of the most useful reactions in organic 
chemistry, which has been utilized to form carbon-carbon bonds. This reaction is 




which can produce β-amino carbonyl compounds.28 These compounds are very 
valuable intermediates for the synthesis of many pharmaceutical and natural 
products containing nitrogen in their structures. Lawsone derivatives have been 
reported to be prepared through Mannich reaction.49  
In this thesis, a group of lawsone derivatives (45 – 49) was produced by 
the Mannich reaction between lawsone, primary or secondary amine 
(ethanolamine, 3-amino-1-propanol, or diethanolamine), and an aldehyde 
(formaldehyde or benzaldehyde) in ethanol at room temperature in very good 
yield (Scheme 23, Table 7). The yields obtained were in the range of 82% to 
98%. When the same reaction was tried with hexylamine and formaldehyde, TLC 
analysis indicated the formation of additional nonpolar spots, which complicated 
the isolation of the usual product. The structures of 45 – 49 were confirmed by 















Table 7.  The ragents used to synthesize lawsone derivatives via Mannich 
reaction 
























































































Hence, the Mannich reaction worked successfully to attach lawsone to an 
aldehyde and an amine. Next, we tried to use Mannich reaction to attach 
lawsone with glucose (Scheme 24). First D-glucose was converted to the imidate 
24 as described earlier (Scheme 15). Then, tert-butoxycarbonyl (Boc) group was 
used to protect the amine group in 3-amino-1-propanol by reacting with di-tert-
butyl dicarbonate in presence of triethylamine in CHCl3 to afford 50. Compound 
50 was ready to react with 24 in the presence of boron trifluoride diethyl etherate 
BF3O(Et)2 as the catalyst in dichloromethane to provide the desired product (51) 
in 14% yield. After that 51 was treated with sodium methoxide in anhydrous 
methanol to give the de-acetylated intermediate, which was then treated with 
trifluoracetic acid (TFA) - water (95:5) to remove the Boc group, affording 52. 
 The glycosylated amine derivative 52 was reacted with lawsone in the presence 
of formaldehyde in ethanol at room temperature. The formation of 53 was not a 
very clean reaction as TLC showed multiple spots that was in contrast to those 
listed in Table 7. Flash chromatography had to be used to purify 53, which was 
obtained in 15% yield. The structure of 53 was confirmed by 1H NMR data. 
Signals found in both aromatic and sugar regions confirm that lawsone and 











An important element of health care is controlled drug release. In this 
case, a drug is released inside a person. This is a process that occurs at a 
specific time in a specific location. Outside triggers can control radiation-sensitive 
functionalized material, such as radiation. These materials can be utilized during 
controlled and targeted delivery of drugs. Radiation-sensitive functional groups 
are known and studied. However, very few examples of such groups exist. 
Earlier studies show that 2-oxoalkyl group has the capacity to go through a 
radiolytic cleavage. Here, we synthesized a group of molecular probes (1 – 6) 




studied under X-ray radiation at various doses. This was done in order to 
determine the possibility of selective cleavage of the aryl oxo-methyl ester 
linkage. The hydrolytic rate of the ester linkage in molecular probes (1, 2, 4 and 
5, Figure 6) was studied. TLC analysis of the hydrolysis reaction mixture 
indicated that hydrolysis occurred at a faster rate for 1 and 2 than for 4 and 5. 
 Poly-L-glutamic acid (PGA) is a natural polypeptide. It is both 
biodegradable and biocompatible. As a result, it is being exploited for utilization 
as a drug carrier system. In this research, we modified PGA with the lipophilic 
phenacyl group in order to make radiation-sensitive nanomaterials.  Preliminary 
experimental data show that the phenacyl groups grafted on the PGA can be 
selectively cleaved upon radiation with a clinically relevant dose (up to 20 Gy).   
Lawsone is commercially available and it can be obtained from natural 
sources. Lawsone as starting material has been used for the synthesis of 
different biologically active compounds. Lawsone also has biological effects such 
as anticancer and antibacterial activity. In this study lawsone was used as a 
starting material to synthesize lawsone derivatives as potential anticancer 
agents. We are particularly interested in the preparation of glycosylated lawsone 
derivatives. Direct connection of lawsone to glucose through either O-glycosidic 
linkage or C-glycosidic linkage was unsuccessful using various conditions in this 
study. Through a Mannich reaction lawsone was successfully linked to various 
polar amines including a glycosylated amine to provide lawsone derivatives as 
potential anticancer agents. The structures of these lawsone derivatives were 




              
 4. Future work 
	
The first part of the research focuses on the synthesis of probes 1 - 6 to 
study the structure effects on radiolysis efficiency. However, the result of 
radiation study was not clear, therefore further studies are needed. For the 
modification of poly-L-glutamic acid, the phenacyl-modified polymer showed 
some indication of responsiveness to radiation. Therefore, more modifications of 
PGA can be done with different modifying groups. In the second part, the 
Mannich reaction works in providing glycosylated lawsone derivative 53. The 
synthesis of 53 could be repeated to get more material and obtain other 
analytical data including 13C NMR and mass spectrum data- due to time restrain, 
I was not able to complete this part of the work. All the synthesized lawsone 
derivatives (45 – 49 and 53) will be evaluated for anticancer activity. 
Furthermore, other glycosylated lawsone derivatives could be prepared using the 
































































































5. Experimental  
 
  
5.1. General Methods 
 
Thin Layer Chromatography (TLC) was performed on Silica Gel 60-F254 (Silicycle) 
with detection by quenching of fluorescence (254 nm), by dipping into 15% 
solution of H2SO4 and/or Mostaine reagent [ammonium molybdate 
(NH4)6Mo7O24.4H2O (20 mg) and Cerium (IV) sulphate (Ce(SO4)2,0.4 g)  in 10 % 
sulphuric acid (400 ml)] followed by charring on hot heating plate.1H NMR 
spectra were measured at 499.9 MHz (Varian Unity Inova 500 MHz). 13C NMR 
spectra were recorded at 125 MHz on the same instrument. TMS (Me4Si, 0 ppm) 
or solvent peaks were used as reference standard. Column chromatography was 
done on Silica Gel 60 (Silicycle 40-63 m). Elemental analyses were carried out 
on a CEC (SCP) 240-XAAnalyzer instrument by Lakehead University 
Instrumentation Laboratory (LUIL). All commercial reagents were used as 
supplied. Solvents for anhydrous reactions were dried according to literature 
procedures. Dichloromethane was distilled over calcium hydride, methanol was 










5.2. Synthetic Procedures and Structure Characteristics 
 
 6-Oxo-6-(2-oxo-2-phenylethoxy)hexanoic acid (1) and bis(2-oxo-
2-phenylethyl) adipate (9) 
 
 
                           1      9  
      Et3N (1.91 mL, 13.7 mmol, 1 eq.) was added to a solution of 2- 
bromoacetophenone (2.7 g, 13.7 mmol, 1 eq.) and adipic acid (2.0 g, 13.7 
mmol, 1 eq.) in EtOAc (20 mL). The mixture was stirred at room temperature 
overnight. The solid was then filtered and washed using EtOAc. The filtrate 
was concentrated under vacuum and the residue was purified by column 
chromatography on silica gel (hexane/ethyl acetate = 1.5:1, 1:1) to provide 1 
(0.73 g, 20%) as a white powder and 9 (0.47 g, 9%).  
For 1: Rf 0.34 (hexane / ethyl acetate 1:1); 1H NMR: (500 MHz, chloroform-d): 
δ 7.98    –7.89 (m, 1H), 7.63 (m, 1H), 7.56 – 7.47 (m, 2H), 5.38 (s, 2H), 2.56 
(m, 2H), 2.48 –   2.39 (m, 2H), 1.79 (br. s, 2H).13C NMR: (125 MHz, 




65.96, 33.64, 33.47, 24.22, 23.99, 23.96. 
For 9: 1H NMR (500 MHz, chloroform-d):  δ 7.92 (dt, J = 8.4, 1.4 Hz, 4H), 7.66 – 
7.57 (m, 2H), 7.50 (td, 4H), 5.36 (s, 4H), 2.56 (m, 4H), 1.88 – 1.78 (m, 4H). 13C 
NMR (125 MHz, chloroform-d): δ 192.20, 172.73, 134.19, 133.86, 128.85, 
127.75, 65.93, 33.50, 24.26. 
 
6-Oxo-6-(1-oxo-1-phenylpropan-2-yl)oxy)hexanoic acid (2) and 
bis (1-oxo-1-phenylpropan-2-yl)adipate (10) 
  
 
                       2        10 
Adipic acid (1 g, 6.85 mmol, 1 eq.) was dissolved in EtOAc (20 mL) and 
Et3N (0.95 mL, 6.85 mmol, 1 eq.) and bromopropiaphenone (1.46 g, 6.85 mmol, 
1 eq.) was added. The reaction mixture was stirred at room temperature 
overnight. Usual work-up as described for the preparation of compound 1 
followed by column chromatography on silica gel (hexane/ethyl acetate = 1.5:1, 
1:1) provided 2 (0.92 g, 48%) as syrup and 10 (0.85 g, 30%). Compound 10 
was not fully purified. A clean 1H or 13C NMR spectrum for 10 was not obtained. 
For 2: Rf 0.6 (hexane/ethyl acetate 1:1); 1H NMR (500 MHz, chloroform-d) 




Hz, 1H), 7.48 (td, J = 7.8, 1.9 Hz, 2H), 5.97 (q, J = 7.0 Hz, 1H), 2.52 – 2.34 (m, 
4H), 1.71 (m, 4H), 1.53 (d, J = 7.1 Hz, 3H).	13C NMR: (125 MHz, chloroform-d) δ 
197.02, 179.18, 172.75, 134.34, 133.60, 128.77, 128.44, 71.39, 33.52, 24.14, 
23.95, 17.10. Anal.Calcd 2 for C15 H18 O5: C, 64; H, 6.51. Found: C, 64; H, 6.54. 
 
6-{2-[(1, 1’-biphenyl)-4-yl]-2-oxoethoxy}-6-oxohexanoic acid (3) 




Adipic acid (1 g, 6.84 mmol, 1 eq.) was dissolved in EtOAc (20 mL) followed 
by the addition of Et3N (0.90 mL, 6.84 mmol, 1 eq.). Then 2- bromo-4-
phenylacetophenone (1.88 g, 6.84 mmol, 1 eq.) was added.  The reaction 
mixture was stirred at room temperature overnight. The solid was filtered, the 
filtrate was concentrated, and the residue was purified by column 




19%) and 11 (0.27 g, 7%). A clean 1H or 13C NMR spectrum for 11 was not 
obtained.  
For 3: Rf 0.3 (hexane/ethylacetate = 1.5:1),1H NMR (500 MHz, chloroform-d): δ 
11.1 (s, OH), 7.99 (m, 2H), 7.80 (m, 2H), 7.75 – 7.66 (m, 2H), 7.63 (m, 2H), 
7.52 – 7.39 (m, 1H), 5.39 (s, 2H), 2.55 (m, 2H), 2.43 (m, 2H), 1.78 (m, 4H).13C 
NMR (125 MHz, chloroform-d) δ 191,87, 179.62, 172.74, 146.59, 139.59, 
129.00, 128.43, 128.35, 127.47, 127.27, 65.95, 44.97, 33.59, 33.49, 24.24, 
24.05. 
 
6-Oxo-6-(2-oxo-1,2-diphenyl ethoxy) hexanoic acid (4) and bis(2-
oxo-1, 2-diphenylethyl)adipate (12) 
 
 
Adipic acid (0.283 g, 1.94 mmol, 1 eq.) was dissolved in EtOAc (10 mL) 
followed by the addition of Et3N (0.27 mL, 1.94 mmol, 1 eq.). Then 2-bromo-2-
phenylacetophenone (0.5 g, 1.94 mmol, 1 eq.) was added. The mixture was 
stirred at room temperature overnight and diluted with EtOAc (50 mL), was 




over Na2SO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (hexane/ethyl acetate = 2/1) to provide 4 (0.75 g, 
60%) as a white powder and 12 (0.1 g, 10%). 
For 4: Rf 0.37 (hexane/ethyl acetate = 1:1); 1H NMR (500 MHz, chloroform-d) δ 
7.96 – 7.90 (m, 2H), 7.54 – 7.30 (m, 8H), 6.86 (s, 1H), 2.59 – 2.49 (m, 2H), 2.47 
– 2.41 (m, 2H), 1.74 (br s, 4H). 13C NMR: (125 MHz, chloroform-d) δ 193.82, 
179.34, 172.80, 134.56, 133.49, 129.32, 129.13, 128.78, 128.65, 128.63, 77.59, 
33.61, 33.54, 29.69, 24.15, 23.95. 
For 12: 1H NMR (500 MHz, chloroform-d) δ 8.00 – 7.88 (m, 4H), 7.52 – 7.41 (m, 
6H), 7.44 – 7.27 (m, 10H), 6.86 (m, 2H), 2.57 – 2.48 (m, 2H), 2.50 – 2.41 (m, 
2H), 1.81 – 1.70 (m, 4H). 13C NMR: (125 MHz, chloroform-d) δ 193.78, 172.75, 
134.56, 133.52, 133.41, 129.23, 129.06, 128.73, 128.59, 128.58, 77.52, 33.49, 
33.49, 24.11, 24.11. 
 
6-((2-methyl-1-oxo-1-phenylpropan-2-yl)oxy)-6-oxohexanoic acid 
(5) and bis(2-methyl-1-oxo-1-phenylpropan-2-yl)adipate (14) 
 




Adipic acid (0.3 g, 2.05 mmol, 1 eq.) was dissolved in DMF (3 ml). 2-
Hydroxy-2-methylpropiophenone (0.312 mL, 2.05 mmol, 1 eq.) was added 
followed by the addition of 4-N,N-dimethylaminopyridine (DMAP) (0.205 g, 0.205 
mmol, 0.1 eq.) and N,N-diisopropylcarbodimide (DIPCI) (0.48 mL, 3.70 mmol, 1.5 
eq.). The mixture was stirred at room temperature for three days. The solid was 
filtered and washed with  hexane/ethyl acetate (1/1). The filtrate was 
concentrated in vacuo and the residue purified by column chromatography on 
silica gel (hexane /ethylacetate = 3/1) to provide 5 (0.15 g, 19%) as a white 
powder and 14 (0.17 g, 21%). 
               For 5: Rf 0.34 (hexane / ethyl acetate = 2:1); 1H NMR (500 MHz, chloroform-d) δ 
11.57 (s, 1H), 8.02 – 7.95 (m, 2H), 7.53 – 7.46 (m, 1H), 7.41 (t, J = 7.9 Hz, 2H), 
2.25 (m, 4H), 1.73 (s, 6H), 1.48 (m, 4H).13C NMR: (125 MHz, chloroform-d) δ 
199.38, 179.58, 172.28, 134.64, 132.45, 128.45, 128.33, 84.28, 45.00, 34.02, 
33.57, 25.37, 23.76, 23.75. 
For 14: 1H NMR (500 MHz, chloroform-d) δ 7.96 (m, 4H), 7.41 – 7.33 (m, 6H), 
2.14 – 2.06 (m, 4H), 1.69 (s, 12H), 1.26 (m, 4H). 13C NMR: (125 MHz, 










Adipic acid (0.27 g, 1.872 mmole, 1 eq.) was dissolved in EtOAc (7 mL), then 
N,N-diisopropylethylamine (0.32 mL, 1.872 mmole, 1 eq.) was added. The 
mixture was stirred for 5 min at room temperature.  3-(Bromoacetyl)-coumarin 
(0.5 g, 1.872 mmole, 1 eq.) was added, and the mixture was stirred at 80	℃ for 
overnight. TLC checked until complete reaction followed by a work up:  by 
filtration of the solid and the concentration of the filtrate under vacuo. The residue 
was purified by column chromatography on silica gel (hexane/ethyl acetate = 1:4) 
to provide compound 6 (0.11 g, 18%) and 16 (0.02 g, 2%). 
For 6: 1H NMR (500 MHz, chloroform-d) δ 8.65 (d, J = 0.8 Hz, 1H), 7.70 (m, 2H), 
7.44 – 7.34 (m, 2H), 5.39 (s, 2H), 2.56 – 2.49 (m, 2H), 2.43 (t, J = 6.7 Hz, 2H), 
1.77 (m, 4H). 13C NMR: (125 MHz, chloroform-d) δ 190.16, 178.32, 172.70, 
159.19, 155.31, 149.10, 135.13, 130.57, 125.31, 121.92, 118.07, 116.87, 69.15, 
33.44, 24.26, 24.01. 




For 16: 1H NMR (500 MHz, chloroform-d) δ 8.65 (s, 2H), 7.74 – 7.63 (m, 4H), 
7.44 – 7.25 (m, 4H), 5.42 (s, 4H), 2.55 (m, 4H), 1.83 (m, 4H).13C NMR (125 MHz, 
chloroform-d) δ 190.15, 172.76, 159.18, 155.30, 149.05, 135.10, 130.57, 125.29, 





oxopropoxy)phenyl) propanoate (18) 
 
 
Compound 17 (0.5 g, 1.69 mmole, 1 eq.) was dissolved in anhydrous 
acetone (3 mL) and then potassium carbonate (0.5 g, 3.38 mmol, 2 eq.), and 
chloroacetone (0.134 mL, 1.69 mmol, 1 eq.) were added. The mixture was stirred 
at 75 ℃ and left for overnight. TLC analysis of the reaction mixture showed no 
new spot; therefore, potassium iodide (0.56 g, 1.69 mmol, 1 eq.) added.  The 
mixture was refluxed for 6 hours until TLC indicated completion of the reaction. 













residue was purified by column chromatography on silica gel (hexane/ethyl 
acetate= 1.5:1) to provide compound 18 (0.24 g, 45%). 
                 Rf 0.38 (hexane/ethyl acetate=1.5:1); 1H NMR (500 MHz, chloroform-d) δ  7.07 
(d, J = 8.3 Hz, 2H), 6.85 – 6.77 (m, 2H), 5.21 (d, J = 8.0 Hz, 1H), 4.57 – 4.49 (m, 
2H), 3.74 – 3.67 (s, 3H), 3.00 (m, 1H),  2.30 (m, 2H), 2.03 (s, 3H), 1.42 (s, 9H). 
13C NMR: (125 MHz, chloroform-d) δ 205.55, 172.38, 171.03, 156.86, 155.16, 
130.53, 129.34, 114.59, 79.74, 77.57, 73.02, 60.34, 54.63, 52.17, 37.37, 28.29, 




hydrochloride (19)   
                
 
 To a solution of 18 (0.1 g, 0.321 mmol, 1 eq.) in EtOAc (1 mL) was added 
hydrogen chloride solution in diethyl ether (HCl.Et2O) (3 mL). The mixture was 
stirred at room temperature for 2 h. The mixture was then concentrated vacuo 









vacuum to provide compound 19 (0.09 g, 97%).1H NMR (500 MHz, DMSO-d6) δ 
8.65 (s, 2H), 7.14 (d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H), 4.80 (s, 2H), 4.22 
(t, J = 6.4 Hz, 1H), 3.68 (s, 3H), 3.09 (m, 2H), 2.16 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 204.58, 169.90, 157.48, 130.97, 127.25, 115.01, 72.48, 53.75, 
53.06, 35.42, 26.70. The 1H and 13C NMR data were in agreement with those 
reported in the literature.16 
 
 




Sodium hydride (0.827 g, 20.68 mmol, 4 eq.) was added to 
tetrahydrofuran (20 mL) and then cholesterol (2.0 g, 5.17 mmol, 1 eq.) was 
added. Tert-butyl bromoacetate (4.032 g, 20.68 mmol, 4 eq.) was then added 
slowly. The mixture was left overnight at 80℃. Water was then added dropwise to 
the reaction mixture until bubbling stopped, and the solvent was removed in 
vacuo. H2O (50 mL) was added and the mixture extracted with DCM (3 x 50 mL). 
The combined organic layer was dried over Na2SO4 and concentrated in vacuo. 







acetate = 5:0.3) to provide compound 20 (0.13 g, 67%). Rf 0.34 (hexane /ethyl 
acetate = 1:1). 1H NMR (500 MHz, chloroform-d) δ 5.38 – 5.33 (m, 1H), 4.01 (s, 
2H), 3.29 – 3.18 (m, 1H), 2.39 (ddd, J = 13.3, 4.8, 2.2 Hz, 1H), 2.31 – 2.22 (m, 
1H), 2.05 – 1.89 (m, 3H), 1.90 – 1.77 (m, 2H), 1.62 – 1.50 (m, 3H), 1.50 (s, 9H, 3 
CH3), 1.46 – 1.36 (m, 1H), 1.35 (m, 3H), 1.25 (m, 1H), 1.20 – 1.06 (m, 5H), 1.09 
– 1.00 (m, 1H), 1.00 (s, 3H, CH3), 0.91 (d, J = 6.4 Hz, 6H, 2CH3  ), 0.87 (d, 6H, 2 
CH3) 0.67 (s, 3H, CH3). 13C NMR (125 MHz, chloroform-d) δ 170.10, 140.62, 
121.81, 81.34, 79.74, 66.04, 56.75, 56.13, 50.12, 42.30, 39.76, 39.51, 38.74, 
37.12, 36.82, 36.18, 35.78, 31.93, 31.86, 28.23, 28.11, 28.01, 24.28, 23.82, 
22.83, 22.57, 21.05, 19.35, 18.71, 11.85.  
  
 
3-O-carboxymethyl-cholesterol (21)  
 
  
To a solution of 20 (1.04 g, 1.86 mmol) dissolved in DCM (15 mL) was 
added trifluoroacetic acid (15 mL) and H2O (1.5 mL) at 0	℃. The mixture was 







(0.48 g, 51%). Rf 0.34 (hexane/ethyl acetate =1:1). 1H NMR (500 MHz, 
chloroform-d) δ 5.37 (d, J = 5.0 Hz, 1H), 4.16 (s, 2H), 3.31 (m, 1H), 2.42 – 2.35 
(m, 2H), 2.28 (m, 2H), 2.05 – 1.94 (m, 4H), 1.94 – 1.83 (m, 4H), 1.74 (m, 1H), 
1.62 – 1.51 (m, 7H), 1.51 – 1.49 (m, 2H), 1.49 – 1.42 (m, 4H), 1.40 – 1.31 (m, 
6H), 1.26 (d, J = 6.4 Hz, 6H), 1.18 – 1.05 (m, 11H), 1.01 (m, 10H), 0.94 – 0.84 
(m, 16H), 0.68 (s, 3H). 
 
Preparation of poly-L-glutamic acid (H+ form) 
 
The commercially available sodium salt of poly-L-glutamic acid (MW 50,000 – 
100,000, 300 mg, 1.98 mmol) was dissolved in double distilled water (dd-H2O) (3 
mL) and cooled in an ice bath. Hydrogen chloride solution (1 M, 3 mL) was 
added drop-wise till pH 1 and the mixture was left to stir for 2 hours. The mixture 
was then centrifuged for 15 min and the supernatant was removed. The solid 
was washed with dd-H2O water until a neutral pH was achieved. The solid was 
dried in the presence of P2O5 under high vacuum overnight to give PGA (H+ form, 
210 mg, 82%).  
 
Preparation of m-PGA-Ph-24 
Poly-L-glutamic acid (H+ form, 125 mg, 0.97 mmol) was dissolved in dry 
dimethylformamide (10 mL) and heated in an oil bath at 40oC. Triethylamine 
(29.4 mg, 40.5 (L, 0.29 mmol) was added and stirred for 5 min, and then bromo-




for 16 h and then cooled to room temperature. A mixture of hexane-ethyl acetate 
(1:1, v/v, 30 mL) was added slowly to the above reaction mixture to precipitate 
out the product. The solid was collected after centrifugation (5000 rpm, 10 min) 
and washed with hexane-ethyl acetate (1:1, v/v, 15 mL×2). The solid was then 
suspended in ethyl acetate (10 mL) and the mixture stirred for 4 h. After 
centrifugation and washing with hexane-ethyl acetate (1:1, v/v, 10 mL), the solid 
was further dried under high vacuum to provide m-PGA-Ph-24 (135 mg) with 
24% of the side chains being modified. 
1H NMR (500 MHz, trifluoroacetic acid-d): δ7.80 (br s, 0.48H, Ar-H), 7.60 (br s, 
0.24H, Ar-H), 7.40 (br s, 0.48H, Ar-H), 5.50 (br s, 0.48 H, OCH2CO), 4.80 (br s, 
1H, H-α), 2.50 – 2.80 (2 br s, 2H, H-γ), 1.90 – 2.40 (m, 2H, H-β).	
 
Preparation of m-PGA-Ph-32 
 Poly-L-glutamic acid (H+ form, 120 mg, 0.93 mmol) was dissolved in dry 
dimethylformamide (DMF, 9 mL) and heated in an oil bath at 40oC. Triethylamine 
(37.4 mg, 51.5 (L, 0.37 mmol) was added and stirred for 5 min, and then 2-
bromoacetophenone (74 mg, 0.37 mmol) was added. The mixture was stirred at 
40oC for 16 h and then cooled to room temperature. A mixture of hexane-ethyl 
acetate (3:1, v/v, 35 mL) was added slowly to the reaction mixture to precipitate 
out the product. The solid was collected after centrifugation (5000 rpm, 10 min) 
and then washed with hexane-ethyl acetate (1:1, v/v, 10 mL, 3X). The solid was 
then suspended in ethyl acetate and the mixture stirred at room temperature for 




provide the crude product (133 mg). The crude product (128 mg) was re-
dissolved in dimethylformamide (DMF, 6 mL) and ddH2O (30 ml) was added to 
give a clear solution. Sodium chloride (3.0 g) was added to the clear solution to 
facilitate precipitation. The solid was collected after centrifugation and then 
washed with ddH2O (3X, 10 mL). The fine powder was further dried under high 
vacuum in the presence of P2O5 for 16 h to provide m-PGA-Ph-32 (100 mg) with 
32% of the side chains being modified.  
1H NMR (500 MHz, trifluoroacetic acid-d): δ 7.80 (br s, 0.64H, Ar-H), 7.60 (br s, 
0.32H, Ar-H), 7.40 (br s, 0.64, Ar-H), 5.50 (br s, 0.64 H, OCH2CO), 4.80 (br s, 1H, 
H-α), 2.50 – 2.70 (2 br s, 2H, H-γ), 2.05 – 2.30 (m, 2H, H-β). 	
 
2,3,4,6-Tetra-O-acetyl-)/b-D-glucopyranose (23) 
           
Glucose (10 g, 55.55 mmol, 1 eq.) was dissolved in pyridine (39 mL) and acetic 
anhydride (28.35 g, 277.77 mmol, 5 eq.) was added. The mixture was stirred at 
room temperature. Then H2O (30 mL) was added in the mixture and stirred for 30 
- 40 min. Cold H2O (500 mL) was added, extracted with EtOAc (3X, 200 mL), and 
washed with HCl [6M, 100 ml] checked pH= 1-2, washed again with saturated 




vacuo to provide compound 22 (23 g, 94%). 22 (10 g, 23.89 mmol, 1 eq.) was 
dissolved in DMF, and ammonium carbonate (5 g, 47.79 mmol, 2 eq.) was 
added. The mixture was stirred at 30 ℃ for 20 h. After that was added CHCl3 (50 
mL) and cooled HCl [1M, 50 mL], extracted with CHCl3 (2X 50 mL). The organic 
layer was washed with saturated NaHCO3 (20 mL) and then with H2O (40 mL), 
dried over Na2SO4, concentrated under vacuo. The residue was purified by 
column chromatography on silica gel (hexane/ethyl acetate = 1:1) to provide 











  23 (1.3 g, 3.72 mmol, 1 eq.) was dissolved in anhydrous DCM (10mL) and 
trichloroacetonitrile (CCl3CN) (1.86 mL, 18.6 mmol, 5 eq.) and 1,8-diazabicyclo 
[5.4.0] undec-7-ene (DBU) (0.1 mL, 0.744 mmol, 0.2 eq.) were added. The 
mixture was stirred at room temperature for 3 h. The mixture was concentrated 















To a solution of 24 (0.81 g, 1.79 mmol, 1.2 eq.) in anhydrous THF (7 mL) 
and 2-hydroxy-1,4-naphthoquinone (lawsone) (0.32 g, 1.49 mmol, 1 eq.) in 
anhydrous DCM (5 mL) at room temperature was added a solution of boron 
trifluoride – diethyl etherate (BF3.O(Et)2) in DCM (0.1 M, 1.25 mL, 0.537 mmol, 
0.3 eq.). The mixture was stirred for 4 h. The reaction was checked by TLC until 
completion and followed by a work-up: quenched with saturated aqueous 
NaCO3H (20 mL), extracted with EtOAc (1X, 50 ml) then (3X, 10 mL), dried with 
Na2SO4, concentrated, purified by column chromatography on silica gel 




(0.59 g, 65%) and 27 (0.27 g, impure). Compound 27 was not clean and was re-
purified by column chromatography on silica gel (toluene/acetone = 5:1) to 
provide 0.16 g (18%) of pure material. 
For 26: 1H NMR (500 MHz, chloroform-d) δ 8.19 – 8.03 (m, 1H), 7.82 – 7.69 (m, 
1H), 6.43 (s, 1H), 5.43 – 5.31 (m, 2H), 5.23 (d, J = 7.5, 1H), 5.17 (dd, J = 10.1, 
8.8Hz, 1H), 4.27 (m, 1H), 4.21 (m, 1H), 3.97 (m, 1H), 2.19 – 2.00 (m, 12H, 4 
CH3).13C NMR: (125 MHz, chloroform-d) δ 207.03, 184.91, 178.78, 170.55, 
170.16, 169.35, 169.09, 157.29, 135.17, 134.32, 133.74, 133.12, 131.60, 130.99, 
126.72, 126.61, 126.46, 126.15, 114.74, 97.65, 77.36, 77.10, 76.85, 75.79, 
72.80, 72.18, 70.46, 70.35, 67.90, 66.45, 61.69, 61.31, 30.94, 29.69, 20.67, 
20.60, 20.58, 20.35.  
For 27: 1H NMR (500 MHz, chloroform-d) δ 8.10 (d, J = 7.5 Hz, 1H), 7.73 (m, 
2H), 7.64 (m, 1H), 6.10 (s, 1H), 5.52 (m, 2H), 5.19 (d, J = 8.2 Hz, 1H), 4.34 (dd, J 
= 12.5, 6.0 Hz, 1H), 4.27 – 4.16 (m, 1H), 4.11 – 4.01 (m, 1H), 2.16 – 2.01 (m, 
12H, 4 CH3).13C NMR: (125 MHz, chloroform-d) δ 207.10, 192.44, 179.62, 
178.59, 170.54, 169.98, 169.42, 169.41, 165.38, 135.53, 134.48, 131.89, 131.18, 
130.34, 129.75, 129.54, 129.00, 128.54, 127.61, 126.97, 124.87, 106.33, 97.17, 
72.90, 71.99, 70.31, 68.48, 67.89, 67.15, 61.50, 44.99, 30.95, 29.71, 20.77, 












To a dissolved solution of glucose (1.033 g, 5.742 mmol, 2 eq.) in DMF 
(25 mL) was added Et3N (3.18 g, 31.58 mmol, 5.5 eq.) and trimethylsilyl chloride 
(TMS-Cl) (4.76 g, 31.58 mmol, 5.5 eq.). The mixture was stirred at room 
temperature. Pentane (100 mL) and ice (100 mL) was added to the reaction 
mixture. The organic layer was separated and the aqueous layer extracted with 
pentane (3x 50 mL). The combined organic layer was washed with H2O (2X, 100 
mL) and then with saturated aqueous NaCl solution (2X, 100 mL), dried over 
Na2SO4, and concentrated to provide 30 (3.5 g, 88%).  
 








To a solution of 30 (3.5 g, 5.74 mmol, 1 eq.) in anhydrous DCM (15 mL) 
was added trimethylsilyl iodide (TMS-I) (6.3 mL, 6.31mmol, 1.1 eq.). The reaction 
mixture was stirred at room temperature for 10 min. The mixture was 








naphthalen-1,4-dione (34) and 4-(2,3,4,6-tetra-O-trimethylsilyl-






2-Hydroxy-1,4-naphthaquinone (0.9 g, 5.22 mmol, 1 eq.) was dissolved in 
THF (10 mL) and sodium bis(trimethylsilyl)amide (NaN(SiMe3)2) (5.2 mL, 28.46 
mmol, 5.5 eq.) was added. The mixture was stirred at room temperature for 10 
min to generate the corresponding enolates of lawsone.  
  
 15-Crown-5 (1.14 g, 5.22 mmol, 1 eq.) was added and the mixture was stirred at 
room temperature for 4 h. The mixture was concentrated under vacuo and DCM 
(60 mL) was added. The organic layer was washed with half saturated aqueous 
NaCl solution (2x 20 mL), dried over Na2SO4, and concentrated, to provide crude 
glycosylated product 34 and 35 (3.7 g). The product was not purified but used 






dione  (45) 
	
 
2-Hydroxy-1,4-naphthoquinone (0.1 g, 0,57 mmol, 1.0 eq.) was dissolved in 
anhydrous ethanol and then ethanolamine (0.035 g, 0.57 mmol, 1.0 eq.) was 
added. The mixture was stirred for 5 min at 45℃. Formaldehyde (0.017 g, 0.57 
mmol 1.0 eq.) was added and the mixture was stirred for 6 h at 45℃. The solid 
was filtered to provide compound 45 (0.109 g, 73%). 1H NMR (500 MHz, DMSO-
d6) δ 8.32 – 8.28 (br s, 1H), 7.95 (dd, J = 7.7, 1.2 Hz, 1H), 7.82 (dd, J = 7.6, 1.3 
Hz, 1H), 7.72 (td, J = 7.5, 1.3 Hz, 1H), 7.58 (td, J = 7.5, 1.3 Hz, 1H), 4.02 (s, 2H), 
3.67 (t, J = 5.4 Hz, 2H), 2.96 (t, J = 5.4 Hz, 2H).13C NMR: (125 MHz, DMSO-d6) δ 
184.96, 182.29, 179.11, 172.14, 135.41, 134.04, 133.97, 133.65, 132.11, 131.98, 















2-Hydroxy-1,4-naphthoquinone (0.1 g, 0.57 mmol, 1.0 eq.) was dissolved in 
anhydrous ethanol and then 3-amine-1-propanol (0.1 mL, 0.55 mmol, 1.1 eq.) 
was added. The mixture was stirred for 20 min at room temperature. 
Formaldehyde (0.1 mL, 0.55 mmol, 1.1 eq.) was added and the mixture was 
stirred at room temperature overnight.  The product was filtered out to provide 
orange solid compound 46 (0.15 g, 94%).  
1H NMR (500 MHz, DMSO-d6) δ 8.17 (br s, 1H), 7.94 (dd, J = 7.7, 1.3 Hz, 
1H), 7.82 (dd, J = 7.6, 1.3 Hz, 1H), 7.70 (td, J = 7.5, 1.4 Hz, 1H), 7.57 (td, J = 7.5, 
1.3 Hz, 1H), 4,089 (s, 1 H), 3.94 (s, 2H), 3.47 (t, J = 6.0 Hz, 2H), 2.93 (t, J = 7.5 
Hz, 2H),1.82 – 1.72 (m, 2H).13C NMR: (125 MHz, DMSO-d6)  δ 185.11, 178.91, 




















2-Hydroxy-1,4-naphthaquinone (0.1 g, 0.57 mmol, 1.0 eq.) was dissolved in 
anhydrous ethanol and then diethanol amine (0.05 mL, 0.57 mmol, 1.0 eq.) was 
added to react for 20 min at room temperature. Formaldehyde (0.1 mL, 0.57 
mmol, 1.0 eq.) was added and the mixture was stirred at 45 ℃ overnight. The 






















2-Hydroxy-1,4-naphthoquinone (0.1 g, 0.57 mmol, 1.0 eq.) was dissolved 
in anhydrous ethanol and ethanolamine (0.038 mL, 0.6 mmol,1.1 eq.) was added 
to react for 20 min at room temperature. Benzaldehyde (0.064 mL, 0.6 mmol, 1.1 
eq.) was added and the mixture was stirred at room temperature.  The product 
was filtered out to provide the orange solid compound 48 (0.16 g, 86%).  
1H NMR: (500 MHz, DMSO-d6) δ 9.82 (br s, 1H), 9.18 (br s, 1H), 7.93 (dd, 
J = 7.7, 1.3 Hz, 1H), 7.83 (dd, J = 7.6, 1.3 Hz, 1H), 7.72 (td, J = 7.6, 1.4 Hz, 1H), 
7.64 – 7.56 (m, 3H), 7.37 (m, 2H), 7.35 – 7.28 (m, 1H), 5.59 (s, 1H), 5.13 (s, 1H), 
3.68 – 3.58 (m, 2H), 3.00 (m, 2H). 13C NMR: (125 MHz, DMSO):  δ 184.80, 
178.78, 171.03, 138.96, 135.10, 134.24, 131.93, 131.35, 128.88, 128.42, 128.29, 







2-Hydroxy-1,4-naphthoquinone (0.1 g, 0.57 mmol, 1.0 eq.) was dissolved 










eq.) was added to reacting for 20 min at room temperature. Benzaldehyde (0.07 
mL, 0.63 mmol, 1.1 eq.) was added and the mixture was stirred at room 
temperature overnight.  The product was filtered out to provide orange solid 
compound 49 (0.198 g, 97%). 1H NMR (500 MHz, DMSO-d6) δ 9.78 (br s, 1H), 
9.00 (br s, 1H), 7.93 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 7.6 Hz, 1H), 7.72 (t, J = 7.6 
Hz, 1H), 7.65 – 7.56 (m, 3H), 7.37 (t, J = 7.5 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 
5.53 (s, 1H), 4.78 (s, 1H), 3.47 (m, 2H), 3.00 (m, 1H), 2.93 (m, 1H), 1.80 (m, 
2H).13C NMR: (125 MHz, DMSO-d6) δ 184.83, 178.72, 171.03, 139.14, 135.17, 
134.21, 131.97, 131.30, 128.82, 128.32, 128.16, 125.81, 125.56, 111.67, 59.29, 







3-Amino-1-propanol (2.1 g, 29.29 mmol, 1.0 eq.) and triethylamine (3.25 g, 
32.21 mmol, 1.1 eq.) were dissolved in CHCl3 (20 mL). Di-tert-butyldicarbonate 
(7.0 g, 32.21 mmol, 1.1 eq.) dissolved in 10 ml CHCl3 was added dropwise to the 
mixture. The mixture was stirred at room temperature overnight.  The mixture 
was then extracted with water (3x 10mL) and the organic layer dried over 




chromatography on silica gel (hexane/ethylacetate= 2:1) and concentrated to 









50 (1.49 g, 3.28 mmol, 1.0 eq.) and 24 (0.574 g, 3.28 mmol, 1.0 eq.) were 
dissolved in DCM (3 mL). BF3OEt2 in DCM solution (0.1 M, 0.9 mL) was added to 
the reaction mixture under argon. This reaction mixture was stirred at room 
temperature overnight.  Sodium bicarbonate solution (20 mL) was added and the 
mixture was extracted with dichloromethane (3 x 20 mL). The organic layer was 
dried with Na2SO4, concentrated, and the residue purified by column 
chromatography on silica gel (hexane /ethyl acetate= 1:1) to provide compound 
51 (0.49 g, 29 %) which was obtained as slightly impure material. 1H NMR (500 
MHz, chloroform-d): δ 5.71 (m, 2H), 5.30 (m, 1H), 5.17 (m, 1H), 5.11 (m, 1H), 
4.34 (m, 1H), 4.15 (m, 2H), 3.95 – 3.84 (m, 1H), 3.78 – 3.70 (m, 1H), 3.72 – 3.65 
(m, 1H), 3.45 – 3.34 (m, 1H), 3.37 – 3.23 (m, 1H), 2.16 – 2.04 (m, 12H), 1.88 – 
1.75 (m, 2H). 
 








51 (0.16 g, 0.316 mmol, 1 eq.) was deprotected to remove the acetyl 
groups by dissolving in anhydrous methanol (3 mL), followed by adding catalytic 
amount of sodium methoxide solution to adjust the reaction mixture to have pH = 
9. The progress of the reaction was monitored by TLC until the reaction was 
complete and followed by a work up: Resin-IR-69 was added until the pH = 7, 
followed by filtration and concentration in vacuo, purified by column 
chromatography on silica gel (chloroform/methanol = 3:0.5) to provide the 
deacetylated intermediate (0.1 g, 94%). The deacetylated intermediate was 
dissolved in trifluoroacetic acid (TFA) (3 mL) and water (0.2 mL) and stirred at rt 
for 30 min when TLC showed the completion of reaction. The reaction was 
worked up by concentration under vacuo to give free amine 52 (0.045 g, 71%) as 











52 (0.45 g, 0.189 mmol, 1.0 eq.) was dissolved in ethanol (3 mL), followed by the 
addition of diisopropylethylamine (42.51 mg, 0.189 mmol, 1.0 eq.). The mixture 
was stirred at room temperature for 5 min under argon, and 2-hydroxy-1,4-
naphthoquinone (32.88 g, 0.189 mmol, 1.0 eq.) was added. The mixture was 
stirred at room temperature for 10 min under argon. After that formaldehyde (5.6 
mg, 0.189 mmol, 1.0 eq.) was added, and the reaction mixture was stirred at 
room temperature overnight. Solvent was then removed and the residue was 
purified by repeated column chromatography (chloroform/methanol= 3:2) and 
(chloroform/methanol/ H2O = 3:2:0.1) to give 53 (0.01 g, 14%) which was slightly 
impure. 1H NMR (500 MHz, chloroform-d) δ 7.97 (d, J = 7.6 Hz, 1H), 7.88 (m, 
1H), 7.63 (m, 1H), 7.49 (m, 1H), 4.33 (d, J = 7.0 Hz, 1H), 4.11 (m, 2H), 3.90 – 
3.83 (m, 3H), 3.77 (m, 2H), 3.52 – 3.41 (m, 4H), 2.60 (m, 1H), 1.31 – 1.23 (m, 
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7.1. 1H and 13C Spectra of Corresponding Compounds 
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